EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions

Marta Giralt iD, Pere Domingo iD, Tania Quesada-López, Rubén Cereijo iD, Francesc Villarroya iD

International Journal of Molecular Sciences · 08.07.2025 · 26 (14) · 6546

DOI: 10.3390/ijms26146546 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.07.2025. Verfasst von Marta Giralt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain. Hauptthemen laut MEDLINE: HIV-Associated Lipodystrophy Syndrome, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Agencia Estatal de Investigación, State Agency of Research (AEI) of the Spanish Ministry of Science (MCIN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of effective antiretroviral therapy in the mid-1990s, which successfully prevented the progression to AIDS in people living with HIV (PLWH), was associated with the appearance of the so-called HIV-associated lipodystrophy. This condition involved subcutaneous fat atrophy; abdominal fat hypertrophy; and, in some cases, lipomatosis. It was also associated with systemic metabolic disturbances, primarily insulin resistance and dyslipidemia. Following the replacement of certain antiretroviral drugs, particularly the thymidine-analog reverse transcriptase inhibitors stavudine and zidovudine, with less toxic alternatives, the incidences of lipoatrophy and lipomatosis significantly declined. However, lipodystrophy resulting from first-generation antiretroviral therapy does not always resolve after switching to newer agents. Although the widespread use of modern antiretroviral drugs—especially integrase strand transfer inhibitors and non-lipoatrophic reverse transcriptase inhibitors such as tenofovir alafenamide—has reduced the incidences of severe forms of lipodystrophy, these regimens are not entirely free of adipose tissue-related effects. Notably, they are associated with weight gain that resembles common obesity and can have adverse cardiometabolic consequences. Recent evidence also suggests the hypertrophy of specific fat depots, such as epicardial and perivascular adipose tissue, in PLWH on last-generation treatments, potentially contributing to increased cardiovascular risk. This evolving landscape underscores the persistent vulnerability of PLWH to adipose tissue alterations. While these morphological changes may not be as pronounced as those seen in classic HIV-associated lipodystrophy, they can still pose significant health risks. The continued optimization of treatment regimens and the vigilant monitoring of adipose tissue alterations and metabolic status remain essential strategies to improve the health of PLWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-Associated Lipodystrophy SyndromeHIV InfectionsAnti-HIV AgentsHumansReverse Transcriptase Inhibitors

Stichwörter der Autor:innen

HIVantiretroviral treatmentlipoatrophylipodystrophylipomatosisobesity

Substanzen

Anti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain.
  • CIBER "Fisiopatología de la Obesidad y Nutrición" (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, 08028 Barcelona, Spain.

ORCID-Profile: Marta Giralt, Pere Domingo, Rubén Cereijo, Francesc Villarroya

Förderung

  • Instituto de Salud Carlos III
  • Agencia Estatal de Investigación
  • State Agency of Research (AEI) of the Spanish Ministry of Science (MCIN)
  • Instituto de Salud Carlos III (ISCIII), Spain
  • European Regional Development Fund (ERDF)
  • Juan de la Cierva-Incorporación” researcher contract
  • European Union Next Generation (EU/PRTR)

Zitieren

APA

Giralt, M., Domingo, P., Quesada-López, T., Cereijo, R., & Villarroya, F. (2025). Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions. International Journal of Molecular Sciences, 26(14), 6546. https://doi.org/10.3390/ijms26146546

Vancouver

Giralt M, Domingo P, Quesada-López T, Cereijo R, Villarroya F. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions. International Journal of Molecular Sciences. 2025;26(14):6546. doi:10.3390/ijms26146546

BibTeX
@article{Giralt2025,
  author = {Giralt, Marta and Domingo, Pere and Quesada-López, Tania and Cereijo, Rubén and Villarroya, Francesc},
  title = {Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {14},
  pages = {6546},
  doi = {10.3390/ijms26146546}
}
Kostenlos starten →